Thursday, January 29, 2015

**MAIN ARENA 1**

**08:00 – 09:30**  
Innovative approaches and hot topics in endovascular interventions

*CHAIRMAN:*
Lawrence Garcia

*MODERATOR:*
Koen Deloose
Josef Tacke
Michael Lichtenberg
William Gray
Sigrid Nikol
Lieven Maene
Erich Minar

**09:10 – 09:15**  
First experience with DCB in AV-fistulas  
*Stephan Duda*

**09:05 – 09:10**  
The role of DCB for SFA-ISR  
*Yann Gouëffic*

**09:15 – 09:20**  
The utility of carbon-dioxide angiography in peripheral interventions  
*Ulf Teichgräber*

**09:20 – 09:25**  
Using ARROW GPSCath to protect wire placement, reduce fluoroscopy while minimizing contrast  
*Michael Lichtenberg*

**09:25 – 09:30**  
Discussion and conclusion

**09:00 – 09:05**  
RELInE-trial: 24 months results with the Viabahn vs. PTA for in-stent restenosis  
*Koen Deloose*

**08:40 – 09:00**  
Live case transmission from Bad Krozingen

**08:10 – 08:25**  
Recorded case via satellite from Münster

**08:05 – 08:10**  
New approaches for drug-eluting stents: The NitiDES programme  
*Dierk Scheinert*

**08:25 – 08:30**  
Results from the Freeway Stent study  
*Josef Tacke*

We are asking all faculty members to strictly respect the given time limits.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 08:35</td>
<td>ILLUMENATE Direct: 12 months results with direct DCB use in femoropopliteal arteries</td>
</tr>
<tr>
<td></td>
<td>Stephan Duda</td>
</tr>
<tr>
<td>08:35 – 08:40</td>
<td>Next generation DCB coating—the EffPac-trial</td>
</tr>
<tr>
<td></td>
<td>Sebastian Sixt</td>
</tr>
<tr>
<td>08:00 – 08:05</td>
<td>Does stent design influence the results of SFA stenting?</td>
</tr>
<tr>
<td></td>
<td>Koen Deloose</td>
</tr>
</tbody>
</table>

*We are asking all faculty members to strictly respect the given time limits.*
Thursday, January 29, 2015

DISCUSSION FORUM

12:30 – 13:30 The great debate: Are all DCB equal?
CHAIRMAN: Michael Jaff
Dierk Scheinert
DISCUSSANT: Gunnar Tepe
Renu Virmani
Stephan Duda
Marianne Brodmann

13:05 – 13:12 DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are continuing
Marianne Brodmann

13:12 – 13:30 Discussion and conclusion

12:58 – 13:05 Lessons learned from INPACT.Deep and why we should stay away from DCB for BTK interventions
Erich Minar

12:51 – 12:58 What next to come in the drug delivery space: Ongoing DCB programmes
Stephan Duda

12:37 – 12:44 Lacking head-to-head trials comparing different DCB studies is comparing apples and oranges – Results have been substantially affected by trial design

12:44 – 12:51 The relevance of Paclitaxel dose and coating for efficacy and safety
Renu Virmani

12:30 – 12:37 There are clear differences in DCB outcomes in the SFA for various coatings – DCB are not equal!
Gunnar Tepe

We are asking all faculty members to strictly respect the given time limits.